MDT-AP-3030
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.645850568
- umap2_2d
- 6.291394457
- umap1_3d
- 2.934598841
- umap2_3d
- -0.032684105
- umap3_3d
- -3.357997132
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.330
- COMPLEMENT+0.220
- TNFA_SIGNALING_VIA_NFKB+0.190
- KRAS_SIGNALING_DN+0.180
- INFLAMMATORY_RESPONSE+0.160
- PI3K_AKT_MTOR_SIGNALING+0.120
- XENOBIOTIC_METABOLISM+0.120
- ANDROGEN_RESPONSE+0.110
- CHOLESTEROL_HOMEOSTASIS+0.080
- HEME_METABOLISM+0.080
Top 10 suppressed
- E2F_TARGETS-0.580
- MYC_TARGETS_V2-0.560
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V1-0.480
- DNA_REPAIR-0.390
- MITOTIC_SPINDLE-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- MTORC1_SIGNALING-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2SFTWNVE | Med | Medulloblastoma | 0.882 |
| 2 | MDT-AP-2913 | Med | Medulloblastoma | 0.824 |
| 3 | TCGA-62-A46S-01A-11R-A24H-07 | — | cohortA3 | 0.818 |
| 4 | BS_KN92S7YQ | Med | Medulloblastoma | 0.813 |
| 5 | MDT-AP-0305 | Med | Medulloblastoma | 0.807 |
| 6 | SRR12475115 | — | — | 0.792 |
| 7 | TCGA-67-6217-01A-11R-1755-07 | — | cohortA1 | 0.791 |
| 8 | MDT-AP-3326 | Med | Medulloblastoma | 0.791 |
| 9 | MDT-AP-3098 | Med | Medulloblastoma | 0.791 |
| 10 | BS_5PJCHF6V | Med | Medulloblastoma | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |